in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
216 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog lipid peroxydation 190<br />
❚ assay list & <strong>in</strong>dex<br />
galan<strong>in</strong> (non-selective)- agonist radioligand 38<br />
GCK (MAP4K2) 145<br />
GHRH 41<br />
GLP-1 39<br />
GLP-1 - agonist radioligand 39<br />
GLP-2 39<br />
glucagon 40<br />
Glucagon 39<br />
glucagon - agonist radioligand 40<br />
Glutamate 86,98<br />
Glyc<strong>in</strong>e 87,99<br />
glyc<strong>in</strong>e (strychn<strong>in</strong>e-<strong>in</strong>sensitive)- antagonist<br />
radioligand 87,99<br />
Glycoprote<strong>in</strong> hormone 40<br />
GnRH (LH-RH)- agonist radioligand 40<br />
Gonadotroph<strong>in</strong>-releas<strong>in</strong>g hormone 40<br />
GPCRs 13<br />
GPCRs (tool-box) 6<br />
GPR119 62<br />
G prote<strong>in</strong>-coupled receptors 13<br />
GR - agonist radioligand 80<br />
GRK2 (ADRBK1) 138<br />
GRK3/BARK2 (ADRBK2) 138<br />
GRK5 138<br />
Growth factors 87<br />
Growth hormone-releas<strong>in</strong>g hormone 41<br />
GSK3a 127<br />
GSK3b 127,128<br />
guanylyl cyclase (activator effect) 181<br />
guanylyl cyclase (<strong>in</strong>hibitor effect) 181<br />
[H]<br />
H 1 41<br />
H 1 - antagonist radioligand 41<br />
H 2 42<br />
H 2 - antagonist radioligand 42<br />
H 2 - <strong>in</strong>verse agonist effect 42<br />
H 2 O 2 scaveng<strong>in</strong>g 190<br />
H 2 O 2 secretion 190<br />
H 3 43<br />
H 3 - agonist radioligand 42,43<br />
H 4 43<br />
H 4 - agonist radioligand 43<br />
HCK 120<br />
HDAC1 158<br />
HDAC2 158<br />
HDAC3 159<br />
HDAC4 159<br />
HDAC5 159<br />
HDAC6 159<br />
HDAC7 159<br />
HDAC8 159<br />
HDAC9 160<br />
HDAC10 160<br />
HDAC11 160<br />
HDACs 158<br />
HER2/ErbB2 k<strong>in</strong>ase 113<br />
HER4/ErbB4 k<strong>in</strong>ase 113<br />
hERG (automated patch-clamp) 94<br />
hERG (conventional patch-clamp) 94<br />
hERG (membrane preparation) - antagonist<br />
radioligand 94<br />
HGK (MAP4K4) 145<br />
high throughput screen<strong>in</strong>g 4<br />
HIPK2 128<br />
HIPK3 128<br />
HIPK4 128<br />
Histam<strong>in</strong>e 41<br />
histam<strong>in</strong>e release (activator effect) 185<br />
histam<strong>in</strong>e release (<strong>in</strong>hibitor effect) 185<br />
HIV-1 protease 171<br />
HMG-CoA reductase 183<br />
HNE (human neutrophil elastase) 168<br />
HNMT (histam<strong>in</strong>e N-methyl transferase) 179<br />
HTRF ® 107<br />
[I]<br />
I 1 - agonist radioligand 88<br />
I 2 - antagonist radioligand 88<br />
IC 50 /EC 50 follow-up studies 204,205,209<br />
IFN-g secretion (<strong>in</strong>hibitor effect) 188<br />
IGF1Rb k<strong>in</strong>ase 114<br />
IGF1R k<strong>in</strong>ase 114<br />
IKKa 152<br />
IKKb 152<br />
IKKe (IKBKE) 152<br />
IL-1b - agonist radioligand 84<br />
IL-1β secretion (<strong>in</strong>hibitor effect) 188<br />
IL-2 - agonist radioligand 84<br />
IL-2 secretion (<strong>in</strong>hibitor effect) 189<br />
IL-4 - agonist radioligand 84<br />
IL-4 secretion (<strong>in</strong>hibitor effect) 189<br />
IL-5 secretion (<strong>in</strong>hibitor effect) 189<br />
IL-6 - agonist radioligand 84<br />
IL-6 secretion (<strong>in</strong>hibitor effect) 189<br />
IL-8 secretion (<strong>in</strong>hibitor effect) 188<br />
IL-10 secretion (<strong>in</strong>hibitor effect) 189<br />
Imidazol<strong>in</strong>e 88<br />
<strong>in</strong>ducible NOS 176,177<br />
Inositol phosphate 181<br />
Insul<strong>in</strong> 88<br />
<strong>in</strong>sul<strong>in</strong> - agonist radioligand 88<br />
Intracellular ligand-gated channels 102<br />
<strong>in</strong> <strong>vitro</strong> ADME profil<strong>in</strong>g 4<br />
<strong>in</strong> <strong>vitro</strong> pharmacology assays 11<br />
<strong>in</strong> <strong>vitro</strong> safety profil<strong>in</strong>g 4<br />
<strong>in</strong> vivo PK 4<br />
ion channel patch-clamp assays 95<br />
Ion channels 93<br />
Ion transport systems 186<br />
IP 3 - agonist radioligand 102,181<br />
IP (PGI 2 ) 65<br />
IP (PGI 2 )- agonist radioligand 65<br />
IRAK1 149<br />
IRAK4 150<br />
IRK (InsR) 114<br />
IRK (InsRb) 114<br />
IRR k<strong>in</strong>ase 114<br />
ITK 120<br />
[J]<br />
JAK1 121<br />
JAK2 121<br />
JAK3 121<br />
JNK1 128<br />
JNK1/3 129<br />
JNK2 128<br />
JNK3 129<br />
[K]<br />
K + channels 94<br />
ka<strong>in</strong>ate - agonist radioligand 86,99<br />
kallikre<strong>in</strong> 168<br />
kappa (KOP) 60<br />
kappa (KOP)- agonist radioligand 59<br />
K ATP 95<br />
K ATP - antagonist radioligand 94<br />
KDR k<strong>in</strong>ase (VEGFR2) 115<br />
K<strong>in</strong>ases 107<br />
K V - antagonist radioligand 95<br />
[L]<br />
LANCEUltra ® 107<br />
Lck k<strong>in</strong>ase 121<br />
lead optimization (or SAR) profil<strong>in</strong>g 4<br />
Leukotrienes 44<br />
LIMK1 150<br />
Locations (<strong>Cerep</strong> sites)<br />
back cover<br />
LPA 1 - agonist radioligand 45<br />
LPA 2 45<br />
LPA 3 45<br />
LRRK2 150<br />
LTB 4 secretion (<strong>in</strong>hibitor effect) 187<br />
LTC 4 secretion (<strong>in</strong>hibitor effect) 187<br />
LTK 115<br />
LXRb - agonist radioligand 81<br />
Lyn A k<strong>in</strong>ase 121<br />
Lyn B k<strong>in</strong>ase 121<br />
Lysophosphatidic acid 45<br />
Lysophospholipid 45<br />
[M]<br />
M 1 50<br />
M 1 - antagonist radioligand 50<br />
M 2 51<br />
M 2 - agonist radioligand 51<br />
M 2 - antagonist radioligand 51<br />
M 2 - <strong>in</strong>verse agonist effect 51<br />
M 3 52<br />
M 3 - antagonist radioligand 51<br />
M 4 52<br />
M 4 - agonist radioligand 52<br />
M 4 - antagonist radioligand 52<br />
M 4 - <strong>in</strong>verse agonist effect 52<br />
M 5 53<br />
M 5 - agonist radioligand 53<br />
M 5 - antagonist radioligand 53<br />
MAO-A 179<br />
MAO-A - antagonist radioligand 180<br />
MAO-B 180<br />
MAO-B - antagonist radioligand 180<br />
MAPKAPK2 133<br />
MAPKAPK5 (PRAK) 133<br />
MARK1 133<br />
MARK2 133<br />
MARK3 133<br />
MARK4 133<br />
master service agreement 208<br />
MC 1 47<br />
MC 1 - agonist radioligand 47<br />
MC 2 47<br />
MC 3 48<br />
MC 3 - agonist radioligand 47<br />
MC 4 48<br />
MC 4 - agonist radioligand 48<br />
MC 4 - <strong>in</strong>verse agonist effect 48<br />
MC 5 48<br />
MCH 1 46<br />
MCH 1 - agonist radioligand 46<br />
MCH 2 47<br />
MCH 2 - agonist radioligand 46<br />
MEK1 145<br />
MEK1 (MAP2K1) 145<br />
MEK5 (MAP2K5) 145<br />
MEKK3 (MAP3K3) 146<br />
MEKK4 (MAP3K4) 146<br />
Melan<strong>in</strong> concentrat<strong>in</strong>g hormone 46<br />
Melanocort<strong>in</strong> 47<br />
Melaton<strong>in</strong> 49,89<br />
MELK 134<br />
Membrane ligand-gated channels 97<br />
Mer k<strong>in</strong>ase 115<br />
Metalloproteases 171<br />
MINK 146<br />
Miscellaneous enzymes 182<br />
MKK4/JNK1 146<br />
MKK4/JNK2 146<br />
MKK6 146<br />
MKK6/p38a (mutant active) 147<br />
MLK1 150<br />
MLK2 (MAP3K10) 150<br />
MMP-1 172<br />
MMP-2 172
Change language